Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Adagrasib (MRTX849) | 2326521-71-3 | 99.9% | 100 MG
Supplier: Medchemexpress LLC HY130149100MG
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. It covalently binds to KRAS G12C at cysteine at residue 12, locking the protein in its inactive GDP-bound conformation and inhibiting KRAS-dependent signal transduction.
- Potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C
- Inhibits KRAS-dependent signal transduction
- Demonstrates dose-dependent anti-tumor efficacy in various in vivo models
- Potently inhibits cell growth in KRAS G12C-mutant cell lines
- Being investigated in multiple clinical trials for various cancers with KRAS G12C mutations
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?